Abstract

Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study

Aliment Pharmacol Ther. 2021 Jul;54(2):160-166. doi: 10.1111/apt.16410. Epub 2021 Jun 10.

Antoine Meyer 1 2 3, Laura Semenzato 1, Mahmoud Zureik 1 4, Alain Weill 1, Franck Carbonnel 2 3, Rosemary Dray-Spira 1

 
     

Author information

  • 1EPIPHARE, Épidémiologie des produits de santé, ANSM-CNAM, Saint Denis, France.
  • 2Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
  • 3Université Paris Saclay, Le Kremlin Bicêtre, France.
  • 4Université Versailles Saint-Quentin en Yvelines, Montigny le Bretonneux, France.

Abstract

Background: Recently, the SECURE-IBD study, based on a physician-reported registry, suggested that thiopurines, either alone or combined with anti-TNF, may increase risk of severe COVID-19.

Aims: To compare the risk of severe COVID-19 according to IBD medications in a large and unselected population.

Methods: Using the French national health data system, the risks of hospitalisation and of death or mechanical ventilation for COVID-19 from 15 February 2020 to 31 August 2020 in IBD patients were compared according to IBD treatment (immunomodulators and biologics), using multivariable Cox models adjusted for socio-demographic characteristics, budesonide/corticosteroids and aminosalicylates use, and comorbidities.

Results: Among 268 185 IBD patients, 600 were hospitalised for COVID-19 and 111 of them died or were mechanically ventilated (including 78 deaths). In multivariable analysis, the risk of hospitalisation for COVID-19 did not differ according to IBD treatment category, with adjusted Hazard Ratios (aHR, unexposed patients used as reference) of 0.94 (95%CI: 0.66-1.35) for immunomodulator monotherapy, 1.05 (0.80-1.38) for anti-TNF monotherapy, 0.80 (0.38-1.69) for anti-TNF combination therapy, 1.06 (0.55-2.05) for vedolizumab and 1.25 (0.64-2.43) for ustekinumab. Similarly, the risk of death or mechanical ventilation for COVID-19 did not differ according to IBD treatment.

Conclusions: Immunomodulators and biologics prescribed in patients with IBD do not appear to increase the severity of COVID-19 infection.

 

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.